Lannett Company, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Lannett Company, Inc.
Lannett has launched its internally-developed generic mycophenolate mofetil 200mg/ml oral suspension in the US, highlighting a first-cycle FDA approval as evidence of its capabilities as well as pointing to limited competition on the rival to Roche’s CellCept.
With five “large, durable assets” in its pipeline, Lannett is confident that post approval these products have the potential to transform the company. This includes the generic version of Boehringer Ingelheim’s Spiriva Handihaler (tiotropium bromide) recently added to Lannett’s respiratory generics portfolio.
Lilly partners with Kumquat to discover small molecule IO drug. Kite, Appia Bio collaborate on allogeneic cell therapies. AstraZeneca and Regeneron pursue novel metabolic therapies targeting GPR75. Lexeo and Stelios merge to focus on gene therapies for rare cardiovascular indications.
Lannett has added another respiratory generic to its development partnership with China’s Respirent, in the form of a rival to Boehringer Ingelheim’s tiotropium-based Spiriva Handihaler.
- Generic Drugs
- Other Names / Subsidiaries
- Kremers Urban Pharmaceuticals, Cody Laboratories, Silarx Pharmaceuticals